When should we consider adjuvant chemotherapy for pT1a pN0 HER2+ breast cancer?   

NCCN gives category 2b recommendation for either ER+ or ER-, HER2+ tumors, from the Tolaney NEJM 2015 paper with trastuzumab/paclitaxel.  However, only 68 patients (16.7%) were pT1a and prior registries show 5-year distant recurrence free survivals anywhere from 86-93%.



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Hennepin County Medical Center
How would you deal with a tumor of 3 mm in a 34 yo...
Medical Oncologist at H Lee Moffitt Cancer Center, University of South Florida
If she is ER-, 3mm, 34 years old, I think you can ...
Medical Oncologist at Hennepin County Medical Center
I would assume you mean these with NCCN language: ...
Sign in or Register to read more